You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions
|
|---|---|
| Published in |
The Lancet Diabetes & Endocrinology, February 2016
|
| DOI | 10.1016/s2213-8587(15)00482-9 |
| Pubmed ID | |
| Authors |
Michael A Nauck, Juris J Meier |
| Abstract |
The incretin effect describes the phenomenon whereby oral glucose elicits higher insulin secretory responses than does intravenous glucose, despite inducing similar levels of glycaemia, in healthy individuals. This effect, which is uniformly defective in patients with type 2 diabetes, is mediated by the gut-derived incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). The importance of the incretin effect for the maintenance of glucose homoeostasis is clearly established, and incretin-based therapies are among the most promising new therapies for type 2 diabetes. However, despite the effectiveness of these therapies in many patients, the idea that they restore the incretin effect is a common misconception. In type 2 diabetes, the endocrine pancreas remains responsive to GLP-1 but is no longer responsive to GIP, which is the most likely reason for a reduced or absent incretin effect. Incretin-based drugs, including GLP-1 receptor agonists and dipeptidyl peptidase 4 (DPP-4) inhibitors, stimulate GLP-1 receptors and thus augment insulin secretion in response to both oral and intravenous glucose stimulation, thereby abolishing any potential difference in the responses to these stimuli. These drugs therefore do not restore the defective incretin effect in patients. By contrast, some bariatric surgical procedures enhance GLP-1 responses and also restore the incretin effect in obese individuals with type 2 diabetes. Thus, not all biological actions elicited by the stimulation of GLP-1 receptors lead to quantitative changes to the incretin effect. |
X Demographics
The data shown below were collected from the profiles of 24 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 4 | 17% |
| Canada | 2 | 8% |
| United Kingdom | 2 | 8% |
| Qatar | 1 | 4% |
| Portugal | 1 | 4% |
| Brazil | 1 | 4% |
| Germany | 1 | 4% |
| Russia | 1 | 4% |
| Denmark | 1 | 4% |
| Other | 0 | 0% |
| Unknown | 10 | 42% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 10 | 42% |
| Practitioners (doctors, other healthcare professionals) | 9 | 38% |
| Scientists | 5 | 21% |
Mendeley readers
The data shown below were compiled from readership statistics for 503 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Russia | 1 | <1% |
| Brazil | 1 | <1% |
| Unknown | 501 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 70 | 14% |
| Student > Bachelor | 57 | 11% |
| Student > Ph. D. Student | 52 | 10% |
| Researcher | 48 | 10% |
| Student > Postgraduate | 34 | 7% |
| Other | 88 | 17% |
| Unknown | 154 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 162 | 32% |
| Pharmacology, Toxicology and Pharmaceutical Science | 47 | 9% |
| Biochemistry, Genetics and Molecular Biology | 44 | 9% |
| Nursing and Health Professions | 19 | 4% |
| Agricultural and Biological Sciences | 19 | 4% |
| Other | 47 | 9% |
| Unknown | 165 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 31. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 March 2024.
All research outputs
#1,309,692
of 25,732,188 outputs
Outputs from The Lancet Diabetes & Endocrinology
#793
of 2,162 outputs
Outputs of similar age
#23,455
of 411,934 outputs
Outputs of similar age from The Lancet Diabetes & Endocrinology
#14
of 58 outputs
Altmetric has tracked 25,732,188 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,162 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 76.2. This one has gotten more attention than average, scoring higher than 63% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 411,934 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 58 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 75% of its contemporaries.